Philogen S.p.A (PHIL) Fair Value & Analysis
Healthcare · IT · Market cap €906M
Fair value as of: Jul 7, 2026
From 25 valuation models · updated 34 days ago
Fair value updated Jul 7, 2026, revised from €166.43 to €71.40 (−57.1%) since Jun 25, 2026. Share price −7.0% over the past month.
A strong business, screening 200% undervalued on our models.
What matters now
- The rarer combination: high quality (83/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (€40.93). The market is more pessimistic than our downside scenario.
- The model range is unusually wide (€40.93 to €153.36). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.
How to read this chart
60‑month range €12.21 – €26.55 · fair‑value band €40.93 – €153.36 · the €23.80 price screens below the €71.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 7, 2026.
Analysis
Philogen S.p.A (PHIL) currently trades at €23.80, while our model-based Fair Value estimate is €71.40, implying the stock looks roughly 200.0% undervalued today. The Quality Score stands at 83/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Philogen S.p.A generated revenue of €320M at a net margin of 71.8%. It earns a return on equity of 89.6%. The stock trades on a trailing P/E of 3.9. Fundamentals as of Jul 7, 2026
Our scenario range runs from €40.93 (bear case) to €153.36 (bull case); at €23.80, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 10% below its 52-week high and 26% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 200%, PHIL screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (€265.10) versus Asset-Based (€6.22). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 83 · Market factors (momentum, volatility) 66
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union.
Full company description
Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment of glioblastoma; Darleukin which is in Phase II clinical trial for the treatment of non-small cell lung cancer; Dekavil which is in Phase II clinical trial for the treatment of chronic inflammatory disorders; and Dodekin which is in Phase I clinical trial for the treatment of various solid tumors. It is also involved in the development of small molecule products, including OncoFAP which is in Phase I clinical trial for the treatment of solid tumors; OncoACP3 which is in Phase I clinical trial for the treatment of prostate cancer; and OncoCAIX which is in Phase 1 trial for the treatment of renal cell carcinoma and other hypoxic tumors. The company was founded in 1996 and is headquartered in Sovicille, Italy.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Philogen S.p.A reported revenue of €314M in FY2025 versus €2.5M in FY2021, a compound +235.0%/yr. Reported net income was €230M in FY2025.
Watch PHIL: get an alert when its fair value changes →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Philogen S.p.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Philogen S.p.A (PHIL) overvalued or undervalued?
What is the fair value of PHIL?
What is the quality score of PHIL?
What is the revenue of Philogen S.p.A (PHIL)?
What is the net profit margin of PHIL?
Does Philogen S.p.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Philogen S.p.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.